Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 5, Safety of the intervention up to 3 months: 'All patients in the bleomycin group developed erythema with erosion by the end of the applications, whereas erythema developed in the placebo group. Discomfort was…
1 study
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 2, Safety of the intervention at 5 to 12 months: 'Systemic beta carotene did not cause any adverse effects in 1 study supplementing 10 mg/d (Nagao), and caused adverse effects of varying severity in 9% of…
3 studies
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
SoF 1, Safety of the intervention at 4 to 12 months: '3 studies (1 each evaluating topical acitretin, topical 13-cis-retinoic acid, 200,000 IU per week of vitamin A) found no adverse effects. Systemic 13-cis-retinoic…
4 studies
GRADE not reported
Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Hamuryudan 1998: significant adverse effects including severe sedation, polyneuropathy, loss of libido, and weight gain; a greater number of adverse events was seen for the higher (300 mg) dose; 4 patients withdrew due…
1 study · 101 participants
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Alpsoy 2002: high rate of adverse events including alopecia, leukopenia, and diarrhoea; 18 of 23 patients in the treatment arm experienced mild flu-like symptoms.
1 study · 50 participants
GRADE not reported
Intervention not reported
Adverse effects (anxiety associated with intervention) · parents of preschool‐aged children or expectant parents
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Valaciclovir (long‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
It is very uncertain whether valaciclovir (suppressive regimen changes adverse effects during use of the preventative intervention compared with episodic regimen) (very low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Topical aciclovir (short‐term) showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Thymopentin showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
HSV vaccination showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention · participants with recurrent herpes labialis
Yellow fever vaccination showed no clear difference in adverse effects during use of the preventative intervention compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ presurgical · participants with recurrent herpes labialis
Interferon probably leads to higher adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ postsurgical · participants with recurrent herpes labialis
Interferon showed no clear difference in adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review